Showing 4651-4660 of 4941 results for "".
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Viscot Releases Prep-Resistant Ink Markerhttps://practicaldermatology.com/news/20130611-viscot_releases_prep-resistant_ink_marker/2459516/AllSkin Plus+ with Prep Resistant Ink is the first prep-resistant ink marker that offers maximum visibility and prep resistance on all skin tones. Its VIXL brilliant blue ink provides enhanced visibility even after prep and other fluids and remains visible up to 10 times longer than traditional ink.
- Suneva Selects Quinnova to Co-promote ReFissahttps://practicaldermatology.com/news/20130610-suneva_selects_quinnova_to_co-promote_refissa/2459520/Suneva Medical, Inc. selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special
- SELF Magazine Awards Glytone “Best Night Cream”https://practicaldermatology.com/news/20130516-self_magazine_awards_glytone_best_night_cream/2459542/Glytone won one of SELF Magazine's 14th annual Healthy Beauty Awards, landing the distinction of “Best Night Cream” 2013 for Glytone Anti-aging Night Cream. The publication surveyed more than 1,600 US readers on their favorite beauty products—based on products that deliver on their promise—in five d
- Amgen to Present at ASCOhttps://practicaldermatology.com/news/20130516-amgen_to_present_at_asco/2459543/Amgen will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology Annual Meeting from May 31 to June 4 in Chicago. Abstracts will include study results on talimogene laherparepvec,